CytomX Therapeutics Inc. (CTMX)
NASDAQ:CTMX
Want to see CTMX full AI Analyst Report?
CTMX Stock Chart & Stats
$4.82
-$0.06(-5.83%)
At close: 4:00 PM EST
$4.82
-$0.06(-5.83%)
Day’s Range― - ―
52-Week Range$1.72 - $8.21
Previous CloseN/A
Volume1.08M
Average Volume (3M)3.87M
Market Cap
$711.89M
Enterprise Value$450.07M
Total Cash (Recent Filing)$346.71M
Total Debt (Recent Filing)$2.86M
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding217,702,910
10 Day Avg. Volume4,674,376
30 Day Avg. Volume3,874,499
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.93
Price to Sales (P/S)7.71
P/FCF Ratio-7.75
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue12.66
Enterprise Value/Gross Profit12.75
Enterprise Value/Ebitda-7.80
Forecast
1Y Price Target
$11.83Price Target Upside145.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$30.75M
Bulls Say, Bears Say
Bulls Say
Expanded Regeneron PartnershipThe enlarged Regeneron deal materially increases program optionality and near- to long-term funding potential, validating CytomX's Probody platform. Access to up to eight additional programs and large milestone upside supports sustained R&D without sole reliance on internal product revenues.
Strengthened Cash RunwayA materially improved cash position and guidance to H2 2028 reduces near-term financing pressure, allowing focused capital allocation to Varseta-M and other prioritized programs. This runway supports multiple clinical readouts and registrational planning without immediate dependence on dilutive financing.
Differentiated Varseta‑M Clinical ProfileClinically meaningful ORR and PFS in late-line CRC versus low single-digit benchmarks indicate a differentiated therapeutic profile. Completed dose optimization enrollment and a clear path to a pivotal study create a durable path to regulatory engagement and potential commercialization if efficacy and safety hold.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow (~$80M TTM) means the company must manage expenditures and financing carefully; extended development timelines or delayed milestones would increase reliance on partnerships or equity raises, pressuring long-term financial flexibility.
Revenue Volatility From Collaboration TimingRevenue dependence on milestone and collaboration timing produces steep year-over-year swings, complicating predictable funding from operations. This structural volatility increases execution risk and may force additional financing or partnership reliance when milestone receipts are lumpy or delayed.
Safety And Regulatory/Dose‑Selection RiskVarseta-M’s registrational path hinges on balancing efficacy and tolerability; persistent Grade 3 diarrhea or immature OS data could necessitate additional studies or dose compromises, delaying approval and reducing commercial prospects despite promising ORR/PFS signals.
CytomX Therapeutics News
CTMX FAQ
What was CytomX Therapeutics Inc.’s price range in the past 12 months?
CytomX Therapeutics Inc. lowest stock price was $1.72 and its highest was $8.21 in the past 12 months.
What is CytomX Therapeutics Inc.’s market cap?
CytomX Therapeutics Inc.’s market cap is $711.89M.
When is CytomX Therapeutics Inc.’s upcoming earnings report date?
CytomX Therapeutics Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 40 days.
How were CytomX Therapeutics Inc.’s earnings last quarter?
CytomX Therapeutics Inc. released its earnings results on May 07, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.121 by $0.021.
Is CytomX Therapeutics Inc. overvalued?
According to Wall Street analysts CytomX Therapeutics Inc.’s price is currently Undervalued.
Does CytomX Therapeutics Inc. pay dividends?
CytomX Therapeutics Inc. does not currently pay dividends.
What is CytomX Therapeutics Inc.’s EPS estimate?
CytomX Therapeutics Inc.’s EPS estimate is -0.08.
How many shares outstanding does CytomX Therapeutics Inc. have?
CytomX Therapeutics Inc. has 217,702,910 shares outstanding.
What happened to CytomX Therapeutics Inc.’s price movement after its last earnings report?
CytomX Therapeutics Inc. reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.121. Following the earnings report the stock price went down -0.5%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc.?
Currently, no hedge funds are holding shares in CTMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CytomX Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.83 (145.50% Upside)
$11.83 (145.50% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.96%
12-Months-Change
Fundamentals
Return on Equity
-36.61%
Trailing 12-Months
Asset Growth
264.84%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc.
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
CTMX Company Deck
CTMX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear near-term development and regulatory plans for Varseta-M (robust ORR 20%–32% and ~7 months PFS, completed optimization enrollment, combination and expansion strategies), backed by a materially strengthened balance sheet (cash up ~152.9%) and runway into H2 2028. Key risks remain operational and clinical: a large year-over-year revenue decline driven by completed collaborations, modest increases in operating costs, and the need to confirm that Grade 3 diarrhea can be reliably managed in the full optimization cohort and over longer follow-up. Overall, the positive clinical momentum and strong cash position outweigh the near-term financial and clinical uncertainties.View all CTMX earnings summariesCTMX Stock 12 Month Forecast
Average Price Target
$11.83
▲(145.50% Upside)
Technical Analysis
Ownership Overview
0.91% Insiders
14.97% Mutual Funds
35.20% Other Institutional Investors
38.76% Public Companies and
Individual Investors